Exosome-based Drug Delivery Platform
Nanoparticles (NPs) have been widely used in various applications and fields, most notably their use in drug delivery systems (DDS). According to the properties of different NPs, they are designed to be used as delivery vehicles against different diseases. Recently, using exosomes as new potential drug carriers has become a research hotspot, many researchers have begun to try to develop exosome-based DDS.
Exosomes originate from the endocytic pathway and released from intracellular multivesicular bodies (MVBs). Exosome generation involves four steps: budding, invagination, MVB formation, and secretion. Exosomes are cell-derived nanovesicles capable of carrying various materials and enabling intercellular transport of substances, such as proteins, mRNA, microRNA, and lipids. Exosomes allow for more precise and efficient targeting, improving efficacy and reducing side effects. Its excellent biocompatibility, low immunogenicity and biodegradability make it well-tolerated by the human body without causing long-term harm. Exosomes can also remain stable in the bloodstream, thereby increasing their half-life and enhancing their therapeutic potential.
Figure 1. Formation of exosome and microvesicle (Ha, D.; et al. 2016)
In addition to these advantages, exosomes are also highly engineerable and can be modified through a variety of genetic engineering and chemical modification strategies. Exosome-based DDS has been extensively explored by a number of companies, some of which have begun clinical trials using exosomes and their engineered structures in various fields such as bone treatment, diabetes treatment, skin regeneration, and anti-cancer treatment.
Figure 2. Structure and composition of exosomes (Liang, Y.J.; et al. 2021)
Exosome-based Drug Delivery Platform We Offer
At Creative BioMart Nanocage, we have integrated a large number of resources and established an exosome-based drug delivery system, which can provide customized services according to the specific needs of clients. We offer three approaches for loading drugs into exosomes:
- Isolate naive exosomes and incubate with compounds in vitro
- Loading of compounds into parental cells and release into exosomes
- Transfection/infection of parental cells with DNA encoding therapeutically active compounds
In order to optimize the exosome-based delivery system, we also provide various strategies such as genetic engineering and chemical modification to modify exosomes to improve and amplify their characteristics or endow them with new properties, such as transfecting plasmids encoding fusion proteins into donor cells to secrete engineered exosomes with targeting ligands on their surface; insertion of amphiphilic molecules into the lipid bilayer of exosomes; membrane fusion, etc.
Figure 3. Surface engineering of exosomes via genetic/biological manipulation or chemical modification (Liang, Y.J.; et al. 2021)
Provided by Clients
Please inform us of your specific exosome-based drug delivery service details, and we can provide customized solutions for different projects.
Confidentiality Statement
We attach great importance to confidentiality, sign a confidentiality agreement before communicating with you, and adopt multiple firewalls and safeguards to protect your privacy.
Why Choose Us?
Creative BioMart Nanocage provides corresponding exosome-based drug delivery service. We have many years of experience in exosome-based drug delivery, and our services have proven to be very useful for understanding the different stages of nanocage development (even in different fields such as materials science). The Creative BioMart Nanocage team has worked in this field for more than ten years and published his research results in top scientific journals. If you have any demand for gold nanocages modification service, please feel free to contact us.
References
- Liang, Y.J.; et al. Engineering exosomes for targeted drug delivery. Theranostics. 2021.
- Ha, D.; et al. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharmaceutica Sinica B. 2016.
